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We aimed to evaluate the effects of intertrochanteric femoral fractures on mortality, morbidity, and cost of zoledronate treatment
in elderly patients treated by osteosynthesis. Based on Evans classification, 114 patients with unstable intertrochanteric femoral
fractures were treated with osteosynthesis. After the surgical treatment of intertrochanteric fractures, the treatment group (M/F,
24/32; mean age, 76.7 ± SD years) received zoledronate infusion, and the control group (M/F, 20/38; mean age, 80.2 ± SD years)
received placebo. Postoperative control visits were performed at 6-week, 3-month, 6-month, and 12-month time points. Functional
level of patients was evaluated by the modified Harris hip score and Merle d’Aubigné hip score. By 12 months, the mean HHS
in treatment and control groups was 81.93 and 72.9, respectively. For time of death of the patients, mortality was found to be
57.1% (16/28) on the first 3 months and 92.9% (26/28) on the first six months. The mortality rate in the treatment and control
groups was 14.3% (8/56) and 34.5% (20/58), respectively. The use of zoledronic acid after surgical treatment of intertrochanteric
femoral fractures in osteoporotic elderly patients is a safe treatment modality which helps to reduce mortality, improves functional
outcomes, and has less side effects with single dose use per year.
1. Introduction
Intertrochanteric femoral fractures are often seen in the 6th
and 8th decades and associated with morbidity, decrease
in daily functions, and mortality in elderly patients [1,
2]. Although mortality rates range from 15% to 30%, the
femoral fractures particularly show an increase within the
year after the fracture occurs [2, 3]. As higher mortality and
morbidity rates were reported with conservative treatment
in intertrochanteric fractures, surgical treatment and early
weight bearing are regarded as the standard approach [4].
Because of high rate of bone union in intertrochanteric
fractures due to occurring in extra capsular and cancellous
bone, rigid internal determinationmethods are considered as
the first choice in surgical treatment [4, 5]. Osteoporosis has
been considered as themain reason for 75%of the fractures in
the elderly people.Nowadays, 1.3million osteoporosis-related
fractures were informed in the US annually, and 300,000 of
these are hip fractures [6]. However, the data suggest that a
small number of patients with hip fracture actually receive
pharmacologic treatment for osteoporosis [7, 8]. Zoledronic
acid is a potent bisphosphonate used in the treatment of
osteoporosis. It has been especially used in the treatment
of hip and vertebral fractures due to osteoporosis in post-
menopausal women and has been shown in clinical studies
to accelerate fracture healing and to inhibit the formation of
new fractures [6, 7]. The purpose of this study is to assess
the effects of zoledronic acid on mortality and morbidity of
intertrochanteric hip fractures in the patients aged over 65
who underwent surgical osteosynthesis.
2. Materials and Methods
Hundred and twenty elderly (65 years or above) patients with
intertrochanteric femoral fractures who underwent surgical
Hindawi Publishing Corporation
Advances in Orthopedics
Volume 2016, Article ID 3703482, 7 pages
http://dx.doi.org/10.1155/2016/3703482
2 Advances in Orthopedics
osteosynthesis between the years 2012 and 2013 in our clinic
were followed up for 1 year prospectively. The number of the
patients was figured out by 95% confidence level and power
analysis to decrease mortality rates from 25% to 15% and 55
patients were determined for each group.
Exclusion criteria were as follows: age below 65 years,
pathological fractures, being bedridden prior to the fracture,
any disease contraindicated to zoledronic acid, any disease
that creates more than two comorbidities, trauma other than
falling, and additional fractures to intertrochanteric femur
fracture. The study started with 60 patients in each group.
But 4 patients from the zoledronic acid group and 2 from
the control group were excluded from the study due to
the absence in control examinations. Thus, the study was
completed with 114 patients.
All patients were informed about the procedure and were
started to be treated after the approval. Patients were consecu-
tively divided into 2 groups according to the sequential order
of arrival and were randomized, and the first patient was
included in the group to be given zoledronic acid (treatment
group). All patients underwent surgical osteosynthesis and
intertrochanteric antegrade nail (INTERTAN, Trademark of
Smith & Nephew, Reg. US Pat. & TM Off.) of Smith &
Nephew Company was selected as implant. All patients were
asked to walk as much as they can tolerate with the help of a
walker for postoperative 6 weeks.
All patients received 1200mg of calcium carbonate and
1000 IU vitamin D for one year from postoperative day 1.
In the treatment group, 5mg of zoledronic acid was applied
to each patient via 30min IV slow infusion in postoperative
week 2. After administration of zoledronic acid and two
hours of observation, patients were discharged. Sodium
chloride prepared and packaged in the same amount and
size as 100mL zoledronic acid bottles in our university’s
chemistry laboratory has been applied as placebo to the
control group following the same procedure. All patients
underwent bone mineral density measurements after post-
operative day 1 and year 1. All patients were examined with
radiological anteroposterior pelvis and two-way hip X-ray
graph and functionally with the Harris hip score and the
Merle d’Aubigné hip score at the 6th week, 3rd month, 6th
month, and 12th month, postoperatively. In both groups,
patients were categorized and examined according to the
age, gender, affected side, the presence of additional disease,
ASA (American Society of Anesthesiologists) score, timing
of operation, the preferred type of anesthesia, postoperative
complications, and mortality rates. Follow-up period was
lasted for one year in both groups.
The study protocol was approved by local ethics com-
mittee (Date, 21 March 2013; number B.30.2.BAV.0.05.05
Bezmialem Foundation University, Medical Faculty Clinical
Research Ethics Committee).
2.1. Statistical Analysis. A summary of the data was presented
as mean, standard deviation, and percentage. Categorical
data were analyzed by using chi-square test. Variations of
functional scores in intragroup and intergroup combinations
were compared with repeated ANOVA and post hoc Bon-
ferroni method. Group mean survival times were estimated
with Kaplan-Meier method. Comparison of mean survival
times was investigated with Log-Rank test. Quantitative
characteristics of the two groups were analyzed by 𝑡-test,
for independent groups in terms of mean comparisons. Cox
regression model was used to show which of multiple factors
had significant effect onmortality. IBM-SPSS 20 programwas
used for analysis. In all tests, the level of significance was
adjusted to 0.05.
3. Results
Among the 114 patients (M/F, 44 (38.6%)/70 (61.4)), 56 (49%)
were treated with zoledronic acid (mean age, 76.79 years)
and 58 (51%) with placebo (mean age, 80.28 years). In the
treatment group, 24 (42.9%) patientsweremale and 32 (57.1%)
were female. In the control group, 20 (34.5%) patients were
male and 38 (65.5%) were female. Treatment and control
groups were comparable in terms of gender distribution.
Patients were divided into two groups including the
patients under 80 years old and over 80 years old and
mortality rates were investigated. Mean age of 114 patients
was 78.56 (56 patients in the treatment groupwith the average
of 76.29; 58 patients in the control group with the average of
80.28). 92.8% of the patients who died (8/8 in the treatment
groups; 18/20 in the control group) were found to be over 80
years old.
Patients were evaluated according to the ASA score at
the preoperative stage and the patients with an ASA score
of 5 were excluded from the study. 62 patients (54.4%) were
evaluated as ASA 3-4 and 52 patients (45.6%) were evaluated
asASA 1-2.Therewas no statistical difference between the two
groupswith regard to theASA values (𝑝 > 0.05). Considering
the ASA and mortality relationship, mortality rate in the
patients with ASA 3-4 was observed to be 78.4% (22/28).
The average operation time of the patients was
observed to be 4 days (1–15). 76 patients (66.7%; treatment
group/control group: 38/38) were determined as ≤4 days and
38 patients (33.3%; treatment group/control group: 18/20)
were determined as >4 days and there was no significant
difference between the two groups (𝑝 = 0.791).
While 32 patients (28.1%; treatment group/control group:
13/19) were operated on under general anesthesia, regional
anesthesia was applied to 82 patients (71.9%; treatment
group/control group: 43/39). There was no significant differ-
ence between the two groups in terms of type of anesthesia
(𝑝 = 0.257).
The changes in bone mineral density of the surviving 86
patients at the end of postoperative 1st year were evaluated
by DEXA in order to assess the efficacy of the treatment.
Intergroup and intragroup differences were evaluated by 𝑡-
test. The increase in bone mineral density in the treatment
group was significant compared to the control group and was
consistent with the literature (𝑝 < 0.01) (Table 3).
Twenty-eight (24.6%) of 114 patients, for whom average
follow-up period was calculated as 9.5 months (treatment
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group/control group: 10.6/8.4), died at the end of post-
operative 1st year. While the postoperative mortality rate
in the treatment group was 14.3% (8/56), this percentage’s
being 34.5% (20/58) in the control group was remarkable.
Considering the patients’ time of death, the mortality rate
in the first three months was observed 57.1% (16/28) and
92.9% (26/28) in the first 6 weeks. Then, the data were
analyzed statistically between the two groups and statistically
significant differences were found between the groups (𝑝 <
0.05) (Table 4).
Functional status of the patients was evaluated at the
postoperative 6th week and 3rd, 6th, and 12th months by
Harris hip score and Marlin d’Aubigné score. At the end of
the postoperative 1st year, in the treatment group, average
HHSwas observed as 81.93/100 and averageMarlin d’Aubigné
score as 14.58/16, and in the control group, average HHS
was observed as 72.9/100 and average Marlin d’Aubigné as
12.68/16. Significant difference was determined as a result of
intergroup and intragroup statistical analysis (𝑝 < 0.05).
4. Discussion
Nine-tenth of hip fractures occur in people aged 65 and
above. Half of these are intertrochanteric femoral fractures
[4, 9]. High rate of incidence of intertrochanteric fractures
has been found to be associated with advanced age, increased
comorbidity, increased daily activity, and osteoporosis [10].
Particularly hip fractures associated with osteoporosis cause
high rates of morbidity and mortality with costly long
hospital stay and rehabilitation along with significant loss of
function [11, 12]. Osteoporosis-related mortality may clearly
be associated with death occurring within 6 months after
the hip fracture [13]. In this study, the patients were divided
into two groups to assess the effect of osteoporosis treatment
on mortality and morbidity and some of them were treated
pharmacologically. As the pharmacological agent, zoledronic
acid, one of the bisphosphonates which is the current drug
group of the osteoporosis treatment and administered as
30min IV infusion once a year, was preferred.
Daily application of 5mg IV zoledronic acid at the 90th
day after the hip fracture has been determined to reduce
the formation of new fractures by 35% and the risk of
mortality by 28% [14]. In in vitro studies performed onmouse
calvarium bone cultures, zoledronic acid was determined to
inhibit vitamin D3 induced calcium release more potently
compared to the other five bisphosphonates and to be 100
times more potent compared to pamidronate, 25 times
compared to alendronate, 200 times compared to clodronate,
10 times compared to ibandronate, and 5 times compared to
risedronate [15].
However, the use of oral bisphosphonates with stringent
and complex procurement requirements is becoming very
difficult for patients taking a large number of oralmedications
because of the damage in cognitive and functional status.
As a result, poor adherence to the treatment with oral
bisphosphonates leads to incomplete treatment [16, 17].
In the study about the timing of zoledronic acid, Eriksen
et al. have shown that the medicine reached the maximum
concentration at the postoperative 2nd week and had the
highest efficiency in reducing mortality [18]. We also applied
zoledronic acid to our patients at postoperative 2nd week.
Another point is the calcium and vitamin D support.
Increased bonemetabolism requires high amounts of calcium
and vitaminD for fracture healing and remodeling. Although
there are studies suggesting that oral calcium supplementa-
tion reduces the incidence of fractures, it can be considered
as adjunctive therapy in the treatment of osteoporosis [19, 20].
We have given to all patients from the postoperative first
day oral medication containing 1200mg/day of calcium and
1000 IU of vitamin D.
Patients in both groups were categorized and assessed
according to the age, gender, presence of comorbidities,
the type of fracture, ASA (American Society of Anesthe-
siologists) score, osteoporosis degree, the time for surgery,
preferred type of anesthesia, and the surgery performed.
Although there was no significant difference between the two
groups in terms of gender, ASA, time of operation, and type
of anesthesia, there was statistical difference between the two
groups in terms of age and type of fracture (𝑝 < 0.05).
Considering the literature, intertrochanteric fractures
appear in women two times more than men [21, 22]. In our
study, the distribution was 70 (61.4%) females and 44 (38.6%)
men. There was no difference between groups in terms of
gender distribution. Similar results have been observed in
women (18/70; 25.7%) andmales (10/44; 22.7%) related to the
mortality rates.
The effect of surgical time on patient mortality still
continues to be a topic of discussion. Generally accepted
approach is to correct the medical condition of the patient
immediately and then undergoing surgical procedure [4, 9].
In a retrospective study that included patients over 60 years
old, the time until surgery in patients whose medical condi-
tions have been improved has been proven not to have any
effect on mortality and treatment of medical comorbidities
has been concluded to be an advantage [23]. In our study,
the average time for the patients to be taken to surgery was
determined 4 (1–15) days. 76 (66.7%) patients were operated
on in 4 days or less, and 38 (33.3%) patients were operated on
after 4 days. All patients underwent surgery after stabilization
of themedical conditions.There was no significant difference
between the two groups.
In a 10-year prospective study about hip fractures, mor-
tality in patients with ASA 3-4 was found significantly higher
[12]; however, in a retrospective review, mortality rates of the
patients aged 65–84withASA 3-4were found higher after hip
fracture [24]. In our study, patients were evaluated according
to the ASA classification and ASA 5 was excluded. 62 (54.4%)
patients were determined to be ASA 3-4 and 52 (45.6%)
were ASA 1-2. Although there was no significant difference
between ASA values between the groups, the effect of ASA
onmortality has been evaluated and 22 (78.4%) of 28 patients
who died were observed to be ASA 3-4.
Toker et al., in the study involving 1333 patients, related
to the type of anesthesia in hip fractures, did not find any
differences between the length of hospital stay of patients who
received general and spinal anesthesia and themortality rates
[25]. In our study, regional anesthesia was administered to 82
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6 weeks 7.96 ± 2.50 7.26 ± 3.09 7.65 ± 2.78
3 months 11.54 ± 3.03 9.37 ± 2.87 10.58 ± 3.13
6 months 13.63 ± 3.33 11.11 ± 3.18 12.51 ± 3.48
12 months 14.58 ± 3.08 12.68 ± 2.61 13.74 ± 3.02
𝑝 value 0.020 0.000
(71.9%) patients, and general anesthesia was administered to
32 (28.1%) patients. No significant difference was determined
between the two groups.
Risk factors associated with the occurrence of fractures
become more widespread in increased ages; every 5 years of
growth the risk of hip fracture increases 1.5–2 times [26].The
majority of intertrochanteric fractures occur over 70 years
of age [4, 27, 28]. Lin et al. in the study involving 217 hip
fractures have identified that the occurrence of trochanteric
fracture and being over 80 years of age were a risk factor
for mortality [29]. Wang et al., in a study evaluating 143595
patients with hip fractures retrospectively, have determined
that mortality rates especially increased within the first year
in patients over the age of 80 [30]. 114 patients over 65 years
were enrolled in our study and the mean age was 78.56 (65–
93) (Table 1). Patients in control group were found to be older
(treatment group average age: 76.29; control group average
age: 80.28) and were statistically significant. In addition,
92.8% of all patients who died (26/28) were determined to
be 80 years and above.We believe that especially 80 years and
above is a serious risk factor formortality at the hip fractures.
Osteoporotic hip fractures are the most important causes
of morbidity and mortality [31] and osteoporosis-related
mortality may clearly be associated with deaths occurring
within the 6 months after the hip fracture [32]. 5mg of
zoledronic acid with single dose IV annually is known to
increase the bone mineral density within 1 year [14, 18, 33–
35].With the knowledge thatDEXAmeasurements givemore
accurate results in the evaluation of bone mineral density
[36, 37] and being the golden standard for osteoporosis
detection [38], in our study, bone mineral density in the
postoperative 1st year was assessed by DEXA. Intergroup and
intragroup differences were evaluated by 𝑡-test. Zoledronic
acid was determined to provide significant increase at the
bone mineral density (Table 4) and was seen consistent with
the literature [14, 39, 40].
The primary goal in the treatment of hip fracture is
to bring the patients to the prefracture functional status.
Postoperative functional status of the patients was evaluated
with Harris hip score and the Merle d’Aubigné score. Harris
hip score is commonly used by orthopedic surgeons to
determine pain status of the patients, to assess normal daily
activities of the patients, and to provide information about
hip joint range of motion [32, 41]. Merle d’Aubigné scoring
is done by evaluating pain, walking ability, and joint range










6 weeks 52.01 ± 16.92 44.16 ± 18.00 48.54 ± 17.74
3 months 66.52 ± 15.80 52.75 ± 17.52 60.44 ± 17.86
6 months 78.36 ± 14.86 64.00 ± 17.58 72.01 ± 17.55
12 months 81.93 ± 15.04 72.90 ± 14.55 77.94 ± 15.42
𝑝 value 0.025 0.000
Table 3: Intergroup and intragroup paired 𝑡-test for changes in
𝑇 scores which shows that zoledronic acid provides significant




(𝑁 = 38) 𝑝 value
Pre-op DEXA −2.70 ± 1.01 −2.75 ± 1.19 0.812
Post-op DEXA −2.17 ± 1.10 −2.39 ± 1.16 0.354
𝑝 value <0.001 0.059
Table 4: Analysis of mortality rates between the groups with chi-
square∗ tests which shows that zoledronic acid provides significant







Alive 48 (85.7) 38 (65.5) 86 (75.4)
Dead 8 (14.3) 20 (35.5) 28 (24.6)
Total 56 (100.0) 58 (100.0) 114 (100.0)
∗Pearson chi-square 𝑝 = 0.012.
of motion [32, 42]. Knobe et al. used Merle d’Aubigné and
Harris hip score for comparing functional results of unstable
intertrochanteric hip fractures [32]. In our study, 86 patients
whose follow-up was completed at the end of postoperative
1st year were functionally assessed with Harris hip score
and the Merle d’Aubigné scale at the 6th week, 3rd month,
6th month, and 12th month (Tables 2 and 3). While the
average HSS was 81,93 in treatment group at the end of
postoperative 1st year, it was found to be 72.9 in control
group. While 83.4% (40/48) excellent and very good results
were achieved in treatment group, 57.9% (22/38) excellent
and very good results were obtained in control group. Similar
results were also seen in the Merle d’Aubigné score. While
66.7% (32/48) excellent and good results were obtained in
treatment group, 26.4% (10/38) excellent and good results
were obtained in control group (Tables 2 and 3). In terms of
functional results, Harris hip score andMerle d’Aubigné score
showed parallelism and remained consistently higher in the
zoledronic acid group from the 6th week (Figures 1 and 2).
Amanat et al., in a study conducted on rats with diaphyseal
femur fractures, showed that zoledronic acid increased the
amount of callus, the mineral content, and durability 6
weeks after the fracture, and particularly the concentration
was condensed in the fracture line [43]. Considering that
osteosynthesis has been implemented to all of our patients,













































Figure 2: Intergroups changes on the Harris hip scores for 12
months.
higher functional scores from the 6th week in the group with
zoledronic acid may have been associated with this condition
(Figures 1 and 2). But we believe that further work is needed
on this issue.
Themortality rate in the intertrochanteric fractures varies
between 15 and 30% [4, 30, 44] and most of them occur
within the first year [30, 45–48]. Moran et al. found that
mortality rates are 9%within the first 1month, 19%within the
first 3 months, and 30% within the first year [45]. Davidson
et al. found that the mortality rate is 26% within one year
after the hip fracture at a hospital in New Zealand and 15–
25% in other studies [49, 50] and stated that the highest risk
period was the first 6 months. Also mortality rates of the
patients at the end of 8–12 months are equal to those who
have not had any hip fractures and therefore it is possible to
consider the patients being recovered at the end of one year
[51, 52]. In our study, mortality rate of 114 patients with the
mean follow-up time of 9.54 months because of the deaths
has been found as 24.5% (28/114). The patients’ time of death
has been determined to be 57.1% (16/28) in the first 3 months
and 92.9% (26/28) in the first 6 months and has been found
to be consistent with the literature. There are a number of
studies showing that zoledronic acid decreases the mortality
rate after hip fractures [14, 18, 53, 54]. In our study, while
mortality rate in treatment group was 14.3% (8/56), mortality
rate in the other group was determined to be 34.5% (20/58).
While themean follow-up time was 10,6 months in treatment
group, it was calculated as 8.4 months in control group. It
was remarkable that deaths in both groups occurred within
the first 3 months and we believe that this situation should be
investigated.
Low number of patients despite having been determined
by power analysis and not having used any radiological
scoring, inability to assess joining time, the groups being
nonhomogeneous because of the dying patients, and absence
of comparison group of treatment with the other antiosteo-
porosis treatment constitute insufficient points of the study.
5. Conclusion
The use of zoledronic acid after surgical treatment of
intertrochanteric femoral fractures in osteoporotic over 65-
year-old patients is a safe treatment modality which helps to
reduce mortality, improves functional outcomes, and has less
side effects with single dose use per year.
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